Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
A6NFK2
UPID:
GRCR2_HUMAN
Alternative names:
GRXCR1-like protein; Glutaredoxin domain-containing cysteine-rich protein 1-like protein
Alternative UPACC:
A6NFK2
Background:
Glutaredoxin domain-containing cysteine-rich protein 2, also known as GRXCR1-like protein, plays a crucial role in maintaining cochlear stereocilia bundles essential for sound detection. This protein's involvement in the auditory system underscores its importance in hearing processes.
Therapeutic significance:
Linked to Deafness, autosomal recessive, 101, a condition characterized by moderate to severe bilateral hearing loss without affecting vestibular function, this protein's study could lead to groundbreaking treatments for hearing impairments.